Dier Mardi — SEC Form 4 filings
SEC reporting owner CIK 1574591. 11 Form 4 filings on record with FilingPulse; latest filed 2026-03-06.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-06-14 to 2026-03-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 31 legs across 5 filings — 9,557 shares, $4,493,391 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 1,183 shares @ $427.21 ($505,389) in MADRIGAL PHARMACEUTICALS, INC., filed 2026-03-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | EVP and CFO | 6 | — | 31 legs · 9,557 sh · $4,493,391 | 6 |
| Oric Pharmaceuticals, Inc. (ORIC) | Director | 3 | — | — | 3 |
| Prelude Therapeutics Inc (PRLD) | Director | 2 | — | — | 2 |
Form 4 filings — Dier Mardi
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-06 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Grant/award (A): 5,215 @ $0 · Sale (S): 646 @ $431.94 · Sale (S): 40 @ $425.08 · Sale (S): 420 @ $426.86 · Sale (S): 80 @ $427.85 · Sale (S): 160 @ $429.00 · +8 more | EDGAR |
| 2026-03-02 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Sale (S): 1,183 @ $427.21 | EDGAR |
| 2026-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Option exercise (M): 4,173 @ $251.63 · Sale (S): 320 @ $570.39 · Sale (S): 410 @ $571.99 · Sale (S): 354 @ $573.02 · Sale (S): 717 @ $574.00 · Sale (S): 120 @ $574.95 · +11 more | EDGAR |
| 2025-06-13 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Sale (S): 258 @ $323.04 | EDGAR |
| 2025-03-07 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Grant/award (A): 3,784 @ $0 · Grant/award (A): 6,374 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | MADRIGAL PHARMACEUTICALS, INC. (MDGL) | Sale (S): 1,187 @ $325.89 · Sale (S): 774 @ $323.54 | EDGAR |
| 2025-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Prelude Therapeutics Inc (PRLD) | Grant/award (A): 23,500 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 25,600 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1574591 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →